X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
busulfan (2) 2
busulfan - administration & dosage (2) 2
child (2) 2
child, preschool (2) 2
combined modality therapy (2) 2
disease-free survival (2) 2
hematology (2) 2
hematopoietic stem cell transplantation (2) 2
humans (2) 2
melphalan - administration & dosage (2) 2
oncology (2) 2
remission induction (2) 2
treatment outcome (2) 2
13-cis-retinoic acid (1) 1
abdominal neoplasms - drug therapy (1) 1
abdominal neoplasms - surgery (1) 1
adolescent (1) 1
adult (1) 1
age (1) 1
anc = absolute neutrophil count (1) 1
anticonvulsants - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
autologous stem cell rescue (1) 1
beam = chemotherapy regimen of bcnu, etoposide, aracytin, and melphalan (1) 1
bone neoplasms - drug therapy (1) 1
bone neoplasms - pathology (1) 1
bone neoplasms - therapy (1) 1
bone-marrow transplantation (1) 1
bone-marrow-transplantation (1) 1
bucy2 = chemotherapy regimen of busulphan and cyclophosphamide (1) 1
bumel = chemotherapy regimen of busulphan and melphalan (1) 1
bumeltt = chemotherapy regimen of busulphan, melphalan, and thiotepa (1) 1
busulfan - adverse effects (1) 1
busulphan-melphalan (1) 1
busulphan/melphalan (1) 1
busulphan–melphalan (1) 1
bw = body weight (1) 1
children (1) 1
children older (1) 1
clonazepam - therapeutic use (1) 1
consolidation chemotherapy (1) 1
contraindications (1) 1
cyclophosphamide (1) 1
experience (1) 1
female (1) 1
follow-up studies (1) 1
fsc = forward scatter (1) 1
gene amplification (1) 1
genes, myc (1) 1
hd = hodgkin's disease (1) 1
hdmel = chemotherapy regimen of melphalan (1) 1
hepatic veno-occlusive disease - chemically induced (1) 1
hepatic veno-occlusive disease - etiology (1) 1
high-dose chemotherapy (1) 1
high-risk ewing's sarcoma (1) 1
high-risk neuroblastoma (1) 1
high‐dose chemotherapy (1) 1
immunology (1) 1
index medicus (1) 1
infant (1) 1
kaplan-meier estimate (1) 1
male (1) 1
malignancies (1) 1
management (1) 1
melphalan (1) 1
melphalan prior (1) 1
micma = chemotherapy regimen of mitoxantrone, aracytin, carboplatinum, and methylprednisolone or cyclophosphamide (1) 1
mm = multiple myeloma (1) 1
multimodal therapy (1) 1
multivariate-analysis (1) 1
myeloablative agonists - therapeutic use (1) 1
neoplasm metastasis (1) 1
neuroblastoma (1) 1
neuroblastoma - drug therapy (1) 1
neuroblastoma - secondary (1) 1
neuroblastoma - surgery (1) 1
nhl = non‐hodgkin's lymphoma (1) 1
of-pediatric-oncology (1) 1
pb = peripheral blood (1) 1
pbpc = peripheral blood progenitor cell (1) 1
pediatrics (1) 1
phase-ii (1) 1
phenytoin (1) 1
proportional hazards models (1) 1
randomized-trial (1) 1
sarcoma, ewing - drug therapy (1) 1
sarcoma, ewing - pathology (1) 1
sarcoma, ewing - therapy (1) 1
sc = subcutaneous (1) 1
sdu = single‐donor unit (1) 1
seizures - chemically induced (1) 1
seizures - prevention & control (1) 1
ssc = side scatter (1) 1
stage-4 neuroblastoma (1) 1
stem cells (1) 1
stem-cell transplantation (1) 1
survival analysis (1) 1
thoracic neoplasms - drug therapy (1) 1
thoracic neoplasms - surgery (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatric Blood & Cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 977 - 981
ABSTRACT Background To evaluate long‐term survival of the first cohort of stage‐4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of... 
Busulphan–Melphalan | neuroblastoma | high‐dose chemotherapy | Busulphan-Melphalan | High-dose chemotherapy | Neuroblastoma | STAGE-4 NEUROBLASTOMA | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | RANDOMIZED-TRIAL | ONCOLOGY | PEDIATRICS | HIGH-RISK NEUROBLASTOMA | STEM-CELL TRANSPLANTATION | OF-PEDIATRIC-ONCOLOGY | MULTIVARIATE-ANALYSIS | CHILDREN OLDER | HEMATOLOGY | high-dose chemotherapy | AGE | Myeloablative Agonists - therapeutic use | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Transplantation, Autologous | Consolidation Chemotherapy | Genes, myc | Busulfan - administration & dosage | Neuroblastoma - secondary | Child | Abdominal Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Remission Induction | Abdominal Neoplasms - surgery | Thoracic Neoplasms - surgery | Hepatic Veno-Occlusive Disease - chemically induced | Disease-Free Survival | Melphalan - administration & dosage | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Neuroblastoma - surgery | Thoracic Neoplasms - drug therapy | Transplantation Conditioning | Stem cells | Melphalan | Busulfan | Index Medicus
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 11/1997, Volume 20, Issue 10, pp. 843 - 846
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.